Abstract
Purpose
Renin profiling has been proposed as a method to guide antihypertensive drug selection. This prespecified post-hoc analysis examined the influence of baseline plasma renin activity (PRA) on blood pressure (BP) responses.
Methods
A 16-week, randomized, double-blind, prompted-titration trial evaluated initial valsartan (V)/hydrochlorothiazide (HCTZ) combination therapy versus initial HCTZ or V monotherapy in individuals aged ≥70 years with systolic hypertension. Sitting PRA was measured at baseline, Week 4, and Week 16. Subjects were stratified into 2 groups for analysis: low renin (baseline PRA <0.65 ng/mL/h) or normal-high renin (baseline PRA ≥0.65 ng/mL/h).
Results
PRA data were available in 322/384 subjects: 178 had low PRA and 144 had normal-high PRA. At Week 4, V/HCTZ was more effective than HCTZ or V at reducing mean sitting systolic BP (MSSBP), independent of baseline PRA, with reductions of −16.9, −12.6, and −9.5 mmHg, respectively, in low-renin subjects and −19.4, −11.5, and −8.6 mmHg in normal-high renin subjects. Baseline PRA was similar in responders (subjects not uptitrated at Week 4) and nonresponders (subjects uptitrated at Week 4). In responders, the reactive rise in PRA at Week 4 was related to change in MSSBP, with the greatest increases in PRA observed in the V/HCTZ group. Higher baseline PRA was associated with a greater reactive rise in PRA.
Conclusions
Baseline PRA is not a useful guide to the BP responses of initial combination V/HCTZ in elderly individuals with systolic hypertension.
Similar content being viewed by others
References
Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens. 2003;16:407–15.
Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens. 2004;17:1–7.
Weidmann P, Beretta-Piccoli C, Ziegler WH, et al. Age versus urinary sodium for judging renin, aldosterone, and catecholamine levels: studies in normal subjects and patients with essential hypertension. Kidney Int. 1978;14:619–28.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–52.
Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58.
Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents Developed in Collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114.
Izzo Jr JL, Weintraub HS, Duprez DA, et al. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. J Clin Hypertens. 2011;13:722–30.
Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens. 2008;21:10–3.
Egan BM, Basile JN, Rehman SU, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22:792–801.
Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension. Blood Press. 1997;6:35–43.
Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, et al. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008;21:61–6.
Minami J, Ohno E, Furukata S, Ishimitsu T, Matsuoka H. Pretreatment levels of plasma renin activity predict ambulatory blood pressure response to valsartan in essential hypertension. J Hum Hypertens. 2009;23:683–6.
Nussberger J, Gradman AH, Schmieder RE, et al. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61:1461–8.
Andersen K, Weinberger MH, Constance CC, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2009;10:157–67.
Duprez DA, Botha J, Charney AN, Prescott MF. Comparison of the efficacy of aliskiren-versus ramipril-based treatment regimens on plasma renin concentration and plasma renin activity in elderly patients with systolic hypertension. J Clin Hypertens. 2009;11:A154.
Stanton AV, Dicker P, O’Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens. 2009;22:954–7.
Brown MJ. Renin: friend or foe? Heart. 2007;93:1026–33.
Azizi M, Bissery A, Bura-Riviere A, Menard J. Dual renin-angiotensin system blockade restores blood pressure-renin dependency in individuals with low renin concentrations. J Hypertens. 2003;21:1887–95.
Azizi M, Bissery A, Lamarre-Cliche M, Ménard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004;43:785–90.
Meade TW, Imeson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci (Lond). 1983;64:273–80.
Weber MA, Neutel JM, Cheung DG. Hypertension in the aged: a pathophysiologic basis for treatment. Am J Cardiol. 1989;63:25H–32H.
Mackenzie IS, Brown MJ. Molecular and clinical investigations in patients with low-renin hypertension. Clin Exp Nephrol. 2009;13:1–8.
Acknowledgments
Funding statement/industry support:
This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
The authors wish to thank Michael S. McNamara, MS, and Mary A. Tom, PharmD, of Oxford PharmaGenesis Inc. for assistance in preparing the methods, results, figures, and tables. This assistance was funded by Novartis Pharmaceuticals Corporation. The authors express their appreciation to Colleen Faller of Novartis Pharmaceuticals Corporation for expert assistance in project management (ClinicalTrials.gov identifier: NCT00698646).
Disclosures
HS Weintraub
Consultancies: Gilead. Speakers’ Bureau: Novartis Pharmaceuticals Corporation, Daiichi-Sankyo, Takeda, AstraZeneca, Gilead, Abbott, Kowa. Grant support: none. Stock ownership/financial interests: none.
DA Duprez
Speakers’ Bureau: Novartis Pharmaceuticals Corporation, Forest, Pfizer, Merck. Advisory Board: Novartis Pharmaceuticals Corporation, Pfizer, Abbott. Grant support: Novartis Pharmaceuticals Corporation, Roche. Stock ownership/financial interests: none.
WC Cushman
Consultancies: Novartis Pharmaceuticals Corporation, Takeda, Daiichi-Sankyo. Grant support: Novartis Pharmaceuticals Corporation, GlaxoSmithKline, Merck. Stock ownership/financial interests: none.
D Purkayastha, DH Zappe, and R Samuel
Employees of Novartis Pharmaceuticals Corporation.
JL Izzo Jr
Consultancies: Boehringer-Ingelheim, Forest Laboratories, Novartis Pharmaceuticals Corporation, Daiichi-Sankyo, Takeda. Grant support: GlaxoSmithKline, Novartis Pharmaceuticals Corporation. Stock ownership/financial interests: none.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weintraub, H.S., Duprez, D.A., Cushman, W.C. et al. Antihypertensive Response to Thiazide Diuretic or Angiotensin Receptor Blocker in Elderly Hypertensives Is Not Influenced by Pretreatment Plasma Renin Activity. Cardiovasc Drugs Ther 26, 145–155 (2012). https://doi.org/10.1007/s10557-011-6365-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10557-011-6365-x